Zhitong Finance App learned that in the context of biotech IPOs crushing the AI sector with an average return of 55% and becoming the biggest winner in US stocks in 2026, another clinical-stage biopharmaceutical company supported by top venture capital has joined the listing boom. Braveheart Bio Inc. (BRVE.US), supported by Andreessen Horowitz (a16z), announced on Wednesday the expansion of its IPO, issuing 21.25 million shares at a price of 18 US dollars per share, raising a total of 382.5 million US dollars — not only did the pricing break the previous upper limit of the 15 to 17 US dollar range, but the issuance scale was also significantly larger than the original plan of 18.75 million shares. The San Francisco-based cardiovascular disease drug developer has a market capitalization of approximately $1.27 billion at the IPO price.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.